chrisvoncsefalvay/vaers-outcomes huggingface dataset:
At 15:28 PM Co Lead RN was alerted by observation nurse RN via walkie talkie that she needed assistance with a client. Client was sitting in 30 minute observation chair with his walking cane between his legs and observation RN standing in front of him. Client stated, "the tip of my ears feel hot and tingly." Co Lead RN recommended to client to take off face mask and take deep breaths. Client A&Ox4. Vitals taken by Observation RN: BP LA 183/121, pulse 92, O2 SAT 98%, respirations 20. Client stated, "yesterday at the doctor's my blood pressure was like 198/135. They wanted to send me to the emergency room but I told them no. I relaxed for awhile in the office and then it went down a little to 180 something. I also got a new medicine for it." Co Lead RN emphasized to client that he needed to see his PCP regarding his blood pressure. Client then stated, "I already have a cardiology appointment next week." 15:40 PM Client stated, "You have all the information you need. I've been here for like an hour I am leaving now. I feel fine." Co Lead RN walked with client as standby assist. Client walked with steady gait.
Client felt dizzy, fainted and hit head on cement. No swelling or injury noted. Student c/o L ankle pain, no swelling noted.
pt recv vax & w/in 24-48 hr post vax, pt exp cold sx, joint achiness, & malaise;sx cont;now exp h/a & exhaustion which required a daily rest, in addition to the prev listed sx;
Information has been received from a registered nurse concerning a patient who in 1996 was vaccinated with a dose of VARIVAX (Merck) (Lot# not reported). It was reported that the patient's titers were negative. It was unknown when titers were drawn. The patient sought unspecified medical attention. At the time of the report, the outcome of the patient was unknown. Additional information has been requested.
Report received from a nurse on 03-11-2008.  An 80 year-old male patient received AFLURIA 0.5 ml pre-filled syringe on 14-Oct-2008.  Concomitant medications include Prilosec (omeprazole), which the patient has been taking for many years.  The patient has no known allergies;  no allergies to eggs.  He has had a flu shot every year for the last 15 years with no reactions.  On 21-Oct-2008, seven days after vaccination, the patient experienced hives which were itchy all over his body.  The patient went to the clinic on 23-Oct-2008 and was given a Decadron (dexamethasone) shot.  This helped but the patient reports 30% of the hives remained a few days after the Decadron shot.  The nurse states that 10 days later (31-Oct-2008), the patient still had some hives.  At the time of reporting (03-Nov-2008), the nurse was not sure how the patient was doing.  Awaiting further information.
pt recvd vax; approx 13 hrs later, arm became red, swollen, aching w/ a lump(size of a bee sting);1 day later, devel itching for approx 24-48 hrs;denies any hives, resp distress; c/o ha; has never recvd flu vax prior to this;
Patient had 1 hour of heart palpitations in the middle of the night after receiving booster dose  of Moderna.  Had similar episodes that self resolved after 1st and 2nd doses as well.  No further symptoms.  Patient wanted to report it so it was documented.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On 22-NOV-2017, the patient was vaccinated with improperly stored dose of VARIVAX (dose, frequency and route of administration were not provided) lot# N020014 and expiration date: 17-JUL-2019. The VARIVAX was reconstituted with properly stored dose of sterile diluent (manufacturer unknown). No adverse effect was reported. The vaccine was stored in between 6 degrees Fahrenheit (F) to 14 F for 1 hour and 35 minutes. There was no previous temperature excursion. The digital data logger was involved in recording the temperature excursion.; Sender's Comments: US-009507513-1712USA009051:
c/o dizziness, feeling faint, hperventilating, anxious; hands were cool-skin warm/dry color pink;
shingles; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, 4 days after receiving Shingrix, the patient experienced shingles. On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The reporter was inquiring on the call if it was possible that the patient developed shingles after vaccination with Shingrix.
Been getting nausea every night after the vaccine.; This is a spontaneous report from a contactable consumer, the patient. A 24-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 26Mar2021 at 12:30 (at the age of 24-years-old) as a single dose for COVID-19 immunisation. Medical history included mitral valve prolapse. The patient had known allergy to penicillin, seafood and shellfish. Concomitant medications included TRI SPRINTEC. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. On 26Mar2021 at 19:00 , the patient experienced nausea. She had been getting nausea every night after the vaccine. The adverse event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. The clinical outcome of nausea was not recovered at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pfizer Pediatric (5-11y) dose given to 15-year-old, Reviewed CDC guidance on vaccine errors.  Plan to administer appropriate Pfizer dose for 2nd dose in minimum of 21 days
Vertigo within 48 hrs of vaccine #2 administration. Have tried meclizine, antihistamine.
Narrative: Patient reported swelling of the arm they received their 1st dose of Pfizer Covid vaccine following injection. Patient reported it took nearly 2 weeks for the swelling to resolve. Did not report any interventions needed to manage the swelling.
Patient presented to the ER on 01/05/2022, complaint of cough, shortness of breath, and body aches.  She is unaware of any fevers.  She states that her cough is productive of clear sputum.  She denies any chest pain, abdominal pain, or nausea/vomiting.  She was diagnosed with acute respiratory failure due to COVID-19 and has not achieved medical stability for safe discharge from the hospital, she still left the hospital against medical advise. Pt returned back to the ER on    02/08/2022 with worsening shortness of breath and chest pain.  She notes that her symptoms are worse with exertion, her symptoms will usually be worse at night, and she is unable to lay flat and sleep secondary to the shortness of breath.  She was discharged as she was in stable conditions.  The patient was readmitted  2/11/2022 because of chest pain and shortness of breath.  Patient came in with a 2-3 day history of sharp centralized chest pain that was worse when she laid flat and better when she leaned forward.  She also had increasing shortness of breath that was also worse when she laid flat.    was noted to have a small pericardial effusion on CTA of the chest.  As the patient was continuing to have these symptoms she was admitted to the observation unit for a Cardiology consultation and a 2D echo.  The 2D echo showed  left ventricular ejection fraction of 40-45%, moderately increased left ventricular posterior wall thickness, and a small pericardial effusion.   She was diagnosed with pericarditis.  She recommended aspirin, colchicine, and increasing her lisinopril to 40 mg. She also recommended getting a repeat echocardiogram in 1 week to ensure improvement of her pericarditis.
given pediatric dose instead of adult dose; patient age 22 given pediatric dose; This case was reported by a other health professional via call center representative and described the occurrence of underdose in a 22-year-old female patient who received HBV (Engerix B pediatric) (batch number 34G75, expiry date 15th February 2024) for prophylaxis.   On 18th May 2022, the patient received Engerix B pediatric. On 18th May 2022, unknown after receiving Engerix B pediatric, the patient experienced underdose and adult use of a child product. On an unknown date, the outcome of the underdose and adult use of a child product were unknown.   Additional Information: GSK Receipt Date: 18-MAY-2022 Reporter's Comments: The reporter was an HCP (health care professional).  The reporter stated that this morning (on day of reporting) a patient received a dose Engerix B in right deltoid. The reporter stated that the patient was given pediatric dose of Engerix B instead of adult dose. The reporter also asked that if there was any information she needed to provide the patient. MI (Medical information) provided the phone number and reporter abandoned call prior to transfer. MI (Medical information) agent stated she would call reporter back. AE (adverse event) filed.  The reporter provided the limited information. Additional supportive information: The reporter reported that an adult patient received a pediatric dose of Engerix B, which led to underdose and adult use of child product.
Severe psoriatic arthritis inflammation in left knee leading to swelling, difficulty in bearing weight and walking, pain with any pressure on the knee.   The adverse event continues to worsen rather than resolve.
red rash; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (red rash) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     No Medical History information was reported.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH ERYTHEMATOUS (red rash). At the time of the report, RASH ERYTHEMATOUS (red rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Treatment medication included Zyrtec q12h for rash and itching.
Swelling started soon after the shot on 9/14/09.  Arm is itchy and sore.  9/16 arm is very itchy and sore, it feels like it's in her shoulder.  She feels hot, chills, but no fever (97.8 oral).
This is a spontaneous report from a noncontactable consumer (patient). A 27-year-old (non-pregnant) female patient received BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# unknown), at the age of 27, via an unspecified route of administration, on May 4, 2021, at 12:00, single dose, for COVID-19 immunisation. Medical history not reported. The patient has no known allergies. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On May 5, 2021, at 16:00, patient has had a headache every day since vaccination. The event did not result in a visit to the doctors or other healthcare professional office/clinic/emergency room/department or urgent care. Therapeutic measures not taken as a result of the event. Since the vaccination, patient has not tested for COVID-19. The outcome of headache every day since vaccination: unknown (at the time of report). No follow-up attempts possible. Information about batch/lot number cannot be obtained. No further information expected.
Per phone call from an area urgent care, the patient developed a cellulitis at site of injection - lt deltoid. Patient had follow-up visit at clinic on 12/6, WBC normal and injection site was noted to be slightly tender to touch at center and a flat red rash area around site. Per patient on phone call 12/28/06 she said arm was no longer swollen or red but was still somewhat tender at site. I told the patient I would submit this vaers report.
Patient had  general malaise unknown cause. Onsite EMS was called vitals  99% O2 HR 116. Patient refused evaluation/care and released agianst medical advice.
No adverse event occurred, no treatment needed. Vaccine given to inappropriate age.  Not licensed for this age.
Episodes of vertigo <1 minute long, when getting up from lying position.  Started 2/7/2021 7:00am.
No adverse effects were reported; Patients were administered improperly stored vaccines doses; This spontaneous report was received from a registered nurse, concerning a patient of unspecified age and gender. The patient's pertinent medical history, concurrent conditions, drug reactions, allergies and concomitant medications were not reported.   On 13-APR-2019, the patient was vaccinated with improperly storage doses of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) for prophylaxis, lot #R034700 and expiration date 16-JUN-2020 (strength, dose, frequency and route of administration were not reported); with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) for prophylaxis, lot #R033080 and expiration date 06-JUN-2020 (strength, dose, frequency and route of administration were not reported); and with hepatitis a vaccine, inactivated (VAQTA) for prophylaxis lot #S001485, expiration date 12-MAY-2020 and lot #R012988 and expiration date 30-MAY-2019. No adverse effects were reported.   The temperature excursion was reported as below 36°F (35.4°F) during a time frame of 27 minutes. Previous temperature excursion was reported as below 36°F (35.4°F) during a time frame of 15 minutes.   A digital data logger was involved.    This is one of several reports received from the same  reporter.; Sender's Comments:  US-009507513-1904USA012221: US-009507513-1905USA002744: US-009507513-1905USA002745: US-009507513-1905USA002746: US-009507513-1905USA002747: US-009507513-1905USA002748: US-009507513-1905USA002749: US-009507513-1905USA002750: US-009507513-1905USA002751: US-009507513-1905USA002752: US-009507513-1905USA002753: US-009507513-1905USA002754: US-009507513-1905USA002755: US-009507513-1905USA002756: US-009507513-1905USA002757: US-009507513-1905USA002759: US-009507513-1905USA002760: US-009507513-1905USA002761: US-009507513-1905USA002762: US-009507513-1905USA002763: US-009507513-1905USA002764: US-009507513-1905USA002765: US-009507513-1905USA002766: US-009507513-1905USA002767: US-009507513-1905USA002768: US-009507513-1905USA002769: US-009507513-1905USA002770:
This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (Cold), HEADACHE (Headache) and NAUSEA (Nausea) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. No Medical History information was reported. On 08-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, the patient experienced NASOPHARYNGITIS (Cold), HEADACHE (Headache) and NAUSEA (Nausea). At the time of the report, NASOPHARYNGITIS (Cold), HEADACHE (Headache) and NAUSEA (Nausea) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No relevant concomitant product use was reported. No treatment information was provided.
Patient received 1st Moderna vaccine dose approximately 1 week ago and inadvertently received a dose of Pzifer today. Director was unaware when she took immunizer to vaccinate him.
A couple of lymph nodes swollen, one above the clavicle and another one closer to the neck, both on the left side; Touching them feels tender and a little pain; This is a spontaneous report received from a contactable consumer (patient).  A 52-years-old male patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on 05Apr2021 09:00 AM (Batch/Lot Number: EP6955) as SINGLE DOSE for covid-19 immunisation.  Medical history included Seasonal allergies due to pollen and dust mites from an unknown date and unknown if ongoing. Historical vaccine included first dose of BNT162B2 (lot number=Pfizer EL3247) at Left arm on 16Mar2021 for covid-19 immunization. The medication the patient received within 2 weeks of vaccination was Dulcera inhaler for seasonal allergies. The patient experienced a couple of lymph nodes swollen, one above the clavicle and another one closer to the neck, both on the left side on 05Apr2021 with outcome of recovering, touching them feels tender and a little pain on 05Apr2021 with outcome of recovering.  The events was non-serious. Reported a couple of lymph nodes swollen, one above the clavicle and another one closer to the neck, both on the left side. Touching them feels tender and a little pain. After 3 days the swollen nodes seem to be fading. No treatment received. No covid prior vaccination. No covid tested post vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  No follow-up attempts are needed. No further information is expected.
pt exp an unspecified adverse event following vax;@ the date of this report, the reporter did not know the name of pt, nor what event was exp;this is 1 of 2 pt from this facility to have unspecified adverse exp p/vax lot#4978212
recently diagnosed with a small case of pulmonary embolism; This is a spontaneous report received from non-contactable reporter (Consumer) from a sales representative. A female patient received bnt162b2 (BNT162B2), administered in arm left, administration date Mar2022 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. On an unspecified date, the reporter stated that her mother was recently diagnosed with a small case of pulmonary embolism (medically significant) with outcome of unknown. She's fine and the doctors seem to have overreacted a bit, but it gave us a scare for a little while. The reporter knows the chance of this being related to the vaccine is infinitesimally small, but just in case, the reporter inquired it Pfizer has done any analysis of the vaccine related thrombosis.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Noticed rash after shower.  Reports the rash worsened over couple days.  No fevers or chills, + pruritus that is worse at night.
Administer expired vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) in a 63-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine). On 29-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Administer expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided No treatment medication was provided The pharmacist reported about the administration of expired moderna vaccine that was given as booster shot to patient. The vaccines was stored in freezer, which was taken out one to two vials and place in fridge each day as needed. The Lot number of vaccine was 006C21A (10-Oct-2021)
Initial unsolicited report received from a pharmacist (Director of Pharmacy)on 12 October 2016. This case is linked with 2016SA189772, 2016SA189781, 2016SA189791, 2016SA189792, 2016SA189793, 2016SA189794, 2016SA189795, 2016SA189796, 2016SA189797, 2016SA189798, 2016SA189799, 2016SA189800, 2016SA189801, 2016SA189802, 2016SA189803, 2016SA189804, 2016SA189805, 2016SA189806, 2016SA189807, 2016SA189808, 2016SA189809, 2016SA189810, 2016SA189811, 2016SA189812, 2016SA189813, 2016SA189814, 2016SA189815, 2016SA189816, 2016SA189817, 2016SA189818, 2016SA189819, 2016SA189820, 2016SA189821, 2016SA189822, 2016SA189823, 2016SA189824, 2016SA189825, 2016SA189826, 2016SA189827, 2016SA189828, 2016SA189829, 2016SA189830, 2016SA189831, 2016SA189832, 2016SA189833, 2016SA189834, 2016SA189835, 2016SA189836, 2016SA189837, 2016SA189838, 2016SA189840, 2016SA189841, 2016SA189842, 2016SA189843, 2016SA189844, 2016SA189845, 2016SA189846, 2016SA189847, 2016SA189848. This case involves a patient (age and gender not reported) who was vaccinated with a dose of FLUZONE (batch number: UI669AA, expiration date: 30 June 2017) via intramuscular route (dose in series, dose and site of administration was not reported), on 04 October 2016. Patient's medical history and concomitant medication were not reported. On an unspecified date, (it was reported as Over the past month ) following the vaccination, the patient had experienced sore arm, redness, warm to touch and raised area approximately 2 x 3 inches. Relevant laboratory data was not reported. Ongoing Illness at time of vaccination and Pre-existing physician diagnosed allergies, birth defects, medical conditions (specify) was reported as unknown. Corrective treatment was not reported. The outcome of the events was reported as unknown. List of documents held by sender: none.
rash on trunk, face, neck, head, & some extremities, itching-restless;some cough
Recipient reported a sore throat and an upper body rash on the neck area and parts of the face that eventually faded.
MRI brain  showed Acute to subacute left basal ganglia infarct. She was reevaluated by stroke team, who recommended aspirin and Plavix x 90 days, statin, 30-day event monitor and to follow-up outpatient in 4 to 6 weeks. ED visit to hospital admission within 6 weeks of receiving the COVID vaccine.
Donor completed plasma donation at 2:18 pm and received tetanus immunization at 2:25 pm. Donor then left the plasma center at approximately 3:15 after being observed for any adverse events following immunization. Donor did not exhibit any signs or symptoms of an adverse event and left the plasma center. At approximately 3:25 pm while the donor was waiting outside for the bus she began to feel hot, sweaty, and nauseated, with a decrease in her hearing. She became dizzy and her friend helped walk her to a shaded area where the donor felt like she might pass out, so she sat down and had her friend pour water on her. This was observed by a passerby and the medical staff associate inside the plasma center was alerted. Donor was brought back into the plasma center and was fanned and provided with water and POWERADE, as well as some crackers. Vital signs were monitored and remained stable. Donor recovered and reported that symptoms had resolved, with some persisting tiredness. Donor was able to ambulate independently and left the center in stable condition at approximately 4:05 pm.
Less than 24 hours right deltoid very sore not red, not swollen, Afebrile. Treated with Tylenol/Benadryl